Keyphrases
Autoimmune
100%
Primary Biliary Cirrhosis
66%
Primary Sclerosing Cholangitis
66%
Therapeutic Target
50%
Inflammatory Bowel Disease
50%
Autoimmune Biliary Disease
50%
Chemokines
50%
Chemokine Receptor
50%
Liver Transplantation
50%
Immunogenetics
50%
Genetic Predisposition
50%
Risk Stratification
50%
Major Histocompatibility Complex
50%
Immune Tolerance
50%
Liver-related Mortality
50%
Cholestatic Liver Disease
50%
Immune Response
50%
Cholestasis
50%
Key Discovery
50%
Transplant Activity
50%
Trialists
50%
Hepatobiliary Disease
50%
Immunogenicity
50%
Disease Mechanisms
50%
Mucosal Immunity
16%
CCL20
16%
Risk Pathway
16%
Early Phase Clinical Trials
16%
Emergent Approach
16%
Stratification Tools
16%
Therapeutic Focus
16%
Biologic Pathways
16%
Clinical Efficacy
16%
CXCL10
16%
Therapeutic Candidates
16%
CCR6
16%
Smad7
16%
CXCR3
16%
CCL25
16%
CCR9
16%
Direct Therapy
16%
Enterocyte
16%
Liver Injury
16%
Liver Disease
16%
High Risk
16%
Ursodeoxycholic Acid
16%
Preclinical Imaging
16%
Mechanistic Insight
16%
Patient Care
16%
Disease Course
16%
Disease Heterogeneity
16%
Imaging Findings
16%
Patient Subgroups
16%
International Cohort
16%
Potential Gains
16%
Liver Fibrosis
16%
Patients with Liver Disease
16%
Low Risk
16%
Disease-based
16%
Individualized Assessment
16%
Quality of Life Improvement
16%
Clinical Trials
16%
Clinical Laboratory
16%
Genetic Risk
16%
Copyright
16%
Medicine and Dentistry
Primary Biliary Cirrhosis
60%
Primary Sclerosing Cholangitis
60%
Diseases
60%
Immunogenicity
50%
Liver Disease
50%
Immunity
50%
Liver Graft
50%
Cholestasis
50%
Biliary Tract Disease
50%
Clinician
50%
Immunological Tolerance
50%
Genetic Predisposition
50%
Risk Stratification
50%
Major Histocompatibility Complex
50%
Immunogenetics
50%
Hepatobiliary Disease
50%
Prevalence
10%
Weakness
10%
Liver Fibrosis
10%
Ursodeoxycholic Acid
10%
Cohort Analysis
10%
Clinical Trial
10%
Liver Injury
10%
Quality of Life
10%
Patient Care
10%
Genetic Risk
10%
Disease Course
10%
Immunology and Microbiology
Immunogenetics
50%
Immunity
50%
Primary Biliary Cirrhosis
50%
Chemokine
50%
Chemokine Receptor
50%
Primary Sclerosing Cholangitis
50%
Genetic Predisposition
50%
Major Histocompatibility Complex
50%
Immunogenicity
50%
Immune Tolerance
50%
Inflammatory Bowel Disease
50%
CXCR3
16%
Mucosal Immunity
16%
CCL25
16%
CCL20
16%
CCR9
16%
CXCL10
16%